Data from Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple <i>KRAS</i> Mutations and Inhibits Tumor Growth

Abstract

<div>Abstract<p>Mutations within the oncogene <i>KRAS</i> drive an estimated 25% of all cancers. Only allele-specific <i>KRAS</i> G12C inhibitors are currently available and are associated with the emergence of acquired resistance, partly due to upstream pathway reactivation. Given its upstream role in the activation of KRAS, son of sevenless homolog 1 (SOS1), has emerged as an attractive therapeutic target. Agents that target SOS1 for degradation could represent a potential pan-<i>KRAS</i> modality that may be capable of circumventing certain acquired resistance mechanisms. Here, we report the development of two SOS1 cereblon-based bifunctional degraders, BTX-6654 and BTX-7312, cereblon-based bifunctional SOS1 degraders. Both compounds exhibited potent target-dependent and -specific SOS1 degradation. BTX-6654 and BTX-7312 reduced downstream signaling markers, pERK and pS6, and displayed antiproliferative activity in cells harboring various <i>KRAS</i> mutations. In two <i>KRAS</i> G12C xenograft models, BTX-6654 degraded SOS1 in a dose-dependent manner correlating with tumor growth inhibition, additionally exhibiting synergy with KRAS and MEK inhibitors. Altogether, BTX-6654 provided preclinical proof of concept for single-agent and combination use of bifunctional SOS1 degraders in <i>KRAS</i>-driven cancers.</p></div>